StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Castle Biosciences's pe ratio was 32.3× on Apr 30, 2025, against 100.4× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 202532.3×−100.9
2024Dec 31, 2024133.3×−288.8
2020Oct 30, 2020422.1×+339.3
2019Dec 31, 201982.8×–

More Castle Biosciences figures

See a number that looks wrong?